GSK (NYSE:GSK) Lifted to “Hold” at Barclays

Barclays upgraded shares of GSK (NYSE:GSK) to a hold rating in a research report report published on Tuesday morning, Zacks.com reports.

Other analysts also recently issued reports about the stock. The Goldman Sachs Group started coverage on shares of GSK in a report on Thursday, May 30th. They set a neutral rating and a $47.00 price objective for the company. Citigroup raised shares of GSK to a strong-buy rating in a research report on Monday, June 24th. Argus raised shares of GSK to a strong-buy rating in a research report on Wednesday, August 7th. UBS Group lowered shares of GSK from a buy rating to a neutral rating in a research report on Monday, July 8th. Finally, Jefferies Financial Group increased their price objective on GSK from $52.50 to $53.00 and gave the company a buy rating in a research report on Tuesday, July 2nd. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, GSK presently has an average rating of Buy and a consensus target price of $50.00.

GSK Stock Down 0.4 %

Shares of GSK stock opened at $43.75 on Tuesday. GSK has a 12-month low of $33.67 and a 12-month high of $45.92. The company has a quick ratio of 0.58, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. The stock has a 50 day moving average price of $39.98 and a two-hundred day moving average price of $41.55. The stock has a market capitalization of $90.66 billion, a P/E ratio of 15.85, a PEG ratio of 1.32 and a beta of 0.64.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be issued a dividend of $0.3843 per share. The ex-dividend date is Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a yield of 3.51%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is currently 54.71%.

Institutional Investors Weigh In On GSK

Several hedge funds and other institutional investors have recently made changes to their positions in GSK. Register Financial Advisors LLC acquired a new stake in GSK during the 1st quarter worth $31,000. Ashton Thomas Private Wealth LLC bought a new position in GSK during the 2nd quarter worth approximately $37,000. Richardson Financial Services Inc. bought a new stake in GSK in the fourth quarter valued at approximately $40,000. PrairieView Partners LLC acquired a new stake in GSK in the second quarter worth $47,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of GSK in the 1st quarter valued at $49,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.